Mersana Therapeutics Inc UpRi Clinical Data Update Call Transcript
Good morning, and welcome to Mersana Therapeutics Conference Call and webcast. (Operator Instructions) I would now like to turn the call over to Sarah Carmody, Executive Director, Investor Relations and Corporate Communications. Please proceed.
Good morning. Welcome to Mersana's Conference Call and webcast to report updated interim data from the UpRi ovarian cancer expansion cohort and provide a clinical development strategy update. A replay of today's call will be available on the Investors and media section of our website.
After our prepared remarks, we will open the call for Q&A. Before we begin, please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the federal securities laws. These may include statements about our clinical strategy for our product candidates, progression, design and timing of our clinical studies, including the company's next trial and data from our ongoing clinical
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |